Abstract-Recent evidence suggests that inflammation in the spontaneously hypertensive rat (SHR) is associated with an uncontrolled matrix metalloproteinase (MMP) activity. We hypothesize that the transcription factor nuclear factor kappa B (NFB) is overexpressed in the SHR, enhancing its MMP activity and enzymatic cleavage of the ␤2 adrenergic receptor (␤ 2 AR), thereby diminishing catecholamine-mediated arteriolar vasodilation. NFB expression level and translocation were compared between Wistar Kyoto rat and SHR kidney, heart, and brain. The animals were treated with NFB inhibitor, pyrrolidine dithiocarbamate, for 10 weeks and correlations between NFB and MMP activity were determined. Immunohistochemistry showed that NFB expression is increased in untreated SHR kidney (Ϸ14%) and brain hypothalamus (Ϸ22%) compared to that in Wistar Kyoto rats (PϽ0.05), but not in myocardium and cerebral cortex. After pyrrolidine dithiocarbamate treatment, the SHR systolic blood pressure was reduced to close to Wistar Kyoto rat levels. NFB expression level in treated SHR was also decreased in kidney and hypothalamus compared to nontreated animals (PϽ0.05). Furthermore, MMP-2 and MMP-9 activities in SHR plasma were significantly reduced (Ϸ41%) by pyrrolidine dithiocarbamate treatment. Additionally, zymographic analyses and in situ zymography showed decreased MMP-2 activity in kidney homogenates and decreased MMP-1 and MMP-9 activities in brain. [1] [2] [3] [4] There is increasing evidence suggesting a strong association between hypertension and inflammation, as well as end-organ damage, 3-7 eg, expression of inducible nitric oxide synthase and inflammatory markers, elevated levels of activated leukocytes in the circulation, enhanced leukocytes cytotoxicity, oxidative stress, and apoptosis. [5] [6] [7] [8] [9] [10] [11] [12] We recently obtained evidence that members of the matrix metalloproteinase (MMP) family, 13 known to degrade the extracellular matrix and connective tissue proteins in different physiological and pathological conditions, 14 -16 have elevated levels in hypertension. In the spontaneously hypertensive rat (SHR), elevated levels of MMP-2, MMP-9, and MMP-7 cause direct damage to cells by cleavage of the extracellular domain of several key receptors, which results in diverse cell dysfunctions. 12 For example, proteolytic cleavage of the vasodilatory ␤2 adrenergic receptor (␤ 2 AR) causes arteriolar constriction and blood pressure elevation, 17 cleavage of the extracellular domain of the insulin receptor produces insulin resistance, 18 and cleavage of the vascular endothelial growth factor receptor-2 leads to endothelial cell apoptosis and capillary rarefaction in the SHR. 19 ␤ 2 AR is a cell surface receptor associated with sympathetic nervous system pathways and is involved in mediating smooth muscle vasodilation to balance vascular tone and blood pressure homeostasis. 20, 21 Overexpression of the ␤ 2 AR gene in the endothelium of the carotid artery serves to restore vasorelaxation in SHR. 22 Several studies also have shown a genetic susceptibility of ␤ 2 AR in hypertension, especially the Arg16 allele polymorphism. [23] [24] [25] [26] This evidence raises the question, what induces the expression of MMP in the SHR? MMP can be influenced by a variety of agents and cytokines, such as IL-1, 27,28 and transcription factors, like activating protein-1, signal transducer and activator of transcription, and nuclear factor kappa B (NFB), that bind to specific elements on MMP gene promoters. 13 There is evidence that NFB activation is
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hronic hypertension is associated with enhanced risk for cardiovascular disease, including atherosclerosis, stroke, and renal failure. [1] [2] [3] [4] There is increasing evidence suggesting a strong association between hypertension and inflammation, as well as end-organ damage, [3] [4] [5] [6] [7] eg, expression of inducible nitric oxide synthase and inflammatory markers, elevated levels of activated leukocytes in the circulation, enhanced leukocytes cytotoxicity, oxidative stress, and apoptosis. [5] [6] [7] [8] [9] [10] [11] [12] We recently obtained evidence that members of the matrix metalloproteinase (MMP) family, 13 known to degrade the extracellular matrix and connective tissue proteins in different physiological and pathological conditions, 14 -16 have elevated levels in hypertension. In the spontaneously hypertensive rat (SHR), elevated levels of MMP-2, MMP-9, and MMP-7 cause direct damage to cells by cleavage of the extracellular domain of several key receptors, which results in diverse cell dysfunctions. 12 For example, proteolytic cleavage of the vasodilatory ␤2 adrenergic receptor (␤ 2 AR) causes arteriolar constriction and blood pressure elevation, 17 cleavage of the extracellular domain of the insulin receptor produces insulin resistance, 18 and cleavage of the vascular endothelial growth factor receptor-2 leads to endothelial cell apoptosis and capillary rarefaction in the SHR. 19 ␤ 2 AR is a cell surface receptor associated with sympathetic nervous system pathways and is involved in mediating smooth muscle vasodilation to balance vascular tone and blood pressure homeostasis. 20, 21 Overexpression of the ␤ 2 AR gene in the endothelium of the carotid artery serves to restore vasorelaxation in SHR. 22 Several studies also have shown a genetic susceptibility of ␤ 2 AR in hypertension, especially the Arg16 allele polymorphism. [23] [24] [25] [26] This evidence raises the question, what induces the expression of MMP in the SHR? MMP can be influenced by a variety of agents and cytokines, such as IL-1, 27, 28 and transcription factors, like activating protein-1, signal transducer and activator of transcription, and nuclear factor kappa B (NFB), that bind to specific elements on MMP gene promoters. 13 There is evidence that NFB activation is prominent in damaged kidneys or dysfunctional hearts with upregulation of p65 mRNA, increased NFB binding activity, and elevated inhibitor of kappa kinase activity. 4, 29, 30 NFB is a transcription protein with regions of DNAbinding and dimerization domains, nuclear translocation signal, and binding site for the inhibitor of B, 31 which is involved in regulating genes of the inflammatory cascade. 32, 33 On activation by extracellular stimuli, NFB translocates from the cytoplasm into the nucleus and regulates specific gene expression. 34 The SHR has elevated levels of NFB expression 18 that possibly may be attributable to elevated free radical production induced by excess nitric oxide production and oxidative stress, which have been suggested to have associations with hypertension. 9,10 Thus, we hypothesize, that NFB induces MMP expression in the SHR, which in turn causes receptor cleavage induced by MMP, such as ␤ 2 AR and consequently elevated arteriolar contraction and arterial blood pressure.
In the present study, we explored the possibility of chronic NFB inhibition on MMP expression and receptor cleavage in the SHR as compared to its normotensive control, the Wistar Kyoto rat (WKY). Among several NFB inhibitors, we used pyrrolidine dithiocarbamate (PDTC) as an effective inhibitor that can be administered over several weeks. 29, 32, 35 PDTC attenuates hypertrophy and end-organ damage, and it suppresses inducible nitric oxide synthase as well as superoxide anion formation in the SHR. 7,29,36 -39 Even though PDTC may have several biological effects that are not fully understood, it most likely stabilizes inhibitor of B to prevent the release of NFB rather than acting at the level of the cytoplasmic NFB/inhibitor of B complex or interfering with DNA binding. 29, 32 We determine NFB levels in SHR kidney, heart, and brain by immunohistochemistry, MMP-2 and MMP-9 activities in plasma, and MMP-2, MMP-1, and MMP-9 activities in heart, kidney, and brain by zymography together with the level of ␤ 2 AR proteolytic cleavage as a mechanism that is involved in the arterial pressure elevation.
Materials and Methods
Male SHR at age 13 to 15 weeks and their normotensive controls, the WKY, were treated with the NFB inhibitor PDTC (150 mg/kg per day) in drinking water for a period of 10 weeks. Untreated controls received standard chow and water ad libitum. The systolic blood pressure of 2 animals in each group was measured with the tail-cuff method every week by the same person and at the same time of day.
At the end of the treatment period, the rats were administered general anesthesia (pentobarbital, 50 mg/kg). Selected tissues (brain, heart, and kidney) were removed and frozen sections (10-m thickness for brain and 5-m thickness for kidney and heart) were fixed and labeled with anti-NF〉 p65 rabbit polyclonal antibody (sc-109; Santa Cruz Biotechnology). The antibody recognizes both the inactive form of p65 subunit, bound to p50 and inhibitor of B in the cytoplasm, and the active monomeric form in the nucleus.
To evaluate potential enzymatic cleavage of the ␤ 2 AR, purified rabbit polyclonal antibodies against the extracellular domain of the ␤ 2 AR (against a peptide at the N-terminus, NLS2662; Novus Biologicals) and antibodies against the intracellular domain of the ␤ 2 AR (against a peptide at the C-terminus, M-20, sc-570; Santa Cruz Biotechnology) were used on sequential sections. The primary antibodies were visualized by binding of secondary antibody conjugated to peroxidase activity with diaminobenzidine substrate. Buffer alone or nonspecific purified rabbit immunoglobulin G served as controls. Selected tissue sections were counterstained with diamino-2-phenylindole (DAPI) for location of cell nuclei.
Gelatin zymography with sodium dodecyl sulfate polyacrylamide gels was used to determine plasma protease activity. MMP-2 activity was determined in homogenized tissues using a MMP-2-specific fluorescently quenched substrate. MMP-1 and MMP-9 activities on frozen tissue sections were determined by in situ zymography using a substrate that is cleaved by both MMPs. Lysis of the substrate was assessed by examination under a fluorescence microscope. Immunolabeling intensities and fluorescence light intensity in the zymogra- 
Results

NFB Expression Level
The SHR had higher NFB expression (PϽ0.05) in renal glomerular and tubulointerstitial areas on average by 14% ( Figure 1B , F) and in hypothalamus region of brain by 22% ( Figure 1D , H) compared with WKY (PϽ0.05). The NFB expression levels were not significantly elevated (PϾ0.05) in SHR myocardium ( Figure 1A , E) and cerebral cortex ( Figure  1C , G).
Translocation of NFB
NFB label density was measured in the nucleus and the cell cytoplasm. In renal tubular cells, SHR has a significantly higher NFB label density in the nucleus, and there were no differences in cytoplasm between WKY and SHR ( Figure  2B ). There were no differences of NFB density in cytoplasm between WKY and SHR in cells of renal blood vessel wall. However, SHR had significantly elevated label density in the nucleus than in cytoplasm ( Figure 2A ). In cardiac muscle cells, SHR showed significantly increased label density in the nucleus than in cytoplasm ( Figure 3B ), whereas WKY and SHR had similar levels of label density in cytoplasm. No differences were found between either WKY and SHR or nucleus and cytoplasm in blood vessels of myocardium ( Figure 3A ). In the SHR brain, significantly higher expression in the nucleus was detected in hypothalamus and cells of its blood vessel walls but not in cerebral cortex (Figure 4 ).
Suppression of Blood Pressure by PDTC Treatment
Systolic blood pressure in SHR started to decrease in the second week of PDTC treatment compared with nontreated SHR (153Ϯ7 and 163Ϯ5 mm Hg, respectively, meanϮSD). The time course of blood pressures in SHR during the treatment also showed a difference compared to the nontreated SHR ( Figure 5 ). The meanϮSD of the systolic blood pressure at the end of the treatment was 120Ϯ3 mm Hg in PDTC-treated SHR and was 188Ϯ4 mm Hg in nontreated SHR, whereas the meanϮSD of the systolic blood pressure of the PDTC-treated and nontreated WKY rats were 115Ϯ4 mm Hg and 114Ϯ2 mm Hg, respectively.
NFB Expression Level After PDTC Treatment
The NFB expression level after PDTC treatment was significantly decreased by 12% compared with nontreated SHR in renal glomerular and tubulointerstitial areas ( Figure 1B , F) and brain hypothalamus ( Figure 1D , H), whereas no significant difference were detected between PDTC-treated WKY and nontreated WKY.
Receptor Cleavage of ␤ 2 AR in the SHR
Cleavage of the extracellular domain of ␤ 2 AR was detected by using different antibodies against its intracellular and its extracellular domains. In microvessels of the kidney, SHR had a significantly reduced expression of the extracellular domain of the ␤ 2 AR (PϽ0.01; Figure 6 A, B). A similar trend was found in renal glomerular and tubulointerstitial areas (Figure 6 C, D) . Additionally, the vessels in the myocardium of SHR had lower expression levels of the extracellular domain of ␤ 2 AR (PϽ0.05; Supplemental Figure S1 , please see http://hyper.ahajournals.org). The expression levels of the extracellular domain in the brain were not significantly different in SHR compared to WKY, including hypothalamus (Supplemental Figure S2 , please see http://hyper.ahajournals. org), cerebral cortex (data not shown), and blood vessels (Supplemental Figure S2 ).
Attenuation of MMP Activity in Plasma by PDTC Treatment
Among the MMPs, we measured the MMP-2, MMP-1, and MMP-9 activities after PDTC treatment based on previous evidence showing increased MMP-2 and MMP-9 activities in SHR. 18, 19 The MMP-2 activity in plasma determined by gelatin gel zymography was not different between WKY and SHR. However, the MMP-2 activity was suppressed in both WKY and SHR after PDTC treatment by 14% and 8%, respectively. The pro-MMP-2 activity was suppressed by PDTC only in SHR and not in WKY (Supplemental Figure  S3 , please see http://hyper.ahajournals.org). The SHR has elevated MMP-9 activity compared with WKY. During PDTC treatment, the MMP-9 activity was found to be suppressed in SHR but not in WKY, and the activity was also significantly lower than treated WKY ( Figure S3 ). As control, both MMP-2 and MMP-9 activities were blocked in vitro by metal chelation with EDTA.
Tissue MMP Activity
In kidney homogenates, no difference in MMP-2 activity, determined with a specific fluorescent substrate, was found between WKY and SHR. However, after treatment both WKY and SHR showed decreased MMP-2 activity by 41% (Supplemental Figure S4A , please see http://hyper.ahajournals. org). The MMP-2 activity was not different between WKY and SHR in both heart and brain homogenates and the PDTC treatment had no effect on MMP-2 activity in either organ (Supplemental Figure S4B , C, please see http://hyper.ahajournals. org). In an alternative approach, the MMP-2 activities in brain, heart, and kidney homogenates were confirmed by gel zymography and similar results were found (Supplemental Figure S4D , E, please see http://hyper.ahajournals.org). The MMP-2 activity is blocked in vitro by EDTA (data not shown).
In the kidney, no difference in MMP-1 and MMP-9 activities, measured by in situ zymography, was found between WKY and SHR ( Figure 7A ). In contrast, SHR heart and brain exhibited significantly higher activities than WKY (PϽ0.05; Figure 7B , C). The brain of SHR with PDTC treatment and the kidney of WKY with PDTC have decreased MMP-1 and MMP-9 activities. However, the PDTC treatment did not have an effect on MMP-1 and MMP-9 activities in the heart ( Figure 7B ).
Chronic NFB Inhibition Attenuated ␤ 2 AR Cleavage in the SHR
After inhibiting NFB with PDTC treatment, the extracellular domain density of the ␤ 2 AR was increased by 20% in renal glomerular and tubulointerstitial areas and by 39% in kidney vessels in SHR (Figure 6 ). In the cerebral cortex (data not shown) and hypothalamus, SHR with PDTC treatment also †PϽ0.05 compared to treated spontaneous hypertensive rats in Student t test. Number of rats is indicated in the bar. Scale barϭ100 m.
exhibit significantly elevated ␤ 2 AR levels (Supplemental Figure S2) . No significant differences between these labels before and after PDTC treatment were found in blood vessels of the myocardium (PϾ0.05; Supplemental Figure S1 ).
Discussion
The current observations indicate an increased expression of the nuclear transcription factor NFB in SHR ( Figure 1F, H) . Blockade of the transcription factor with PDTC serves to reduce the expression levels and the translocation into the cell nucleus with reduced MMP activity in kidney and brain (Supplemental Figure S4 ) and a reduction of blood pressure ( Figure 5 ) and cleavage of the extracellular domain of the ␤ 2 AR (Figure 6 and Supplemental Figures S1, S2) .
The expression level of NFB in this study was examined by immunohistochemistry. This approach permits detection of the transcription factor in different tissue regions (eg, endothelial cells vs mast cells or parenchymal cells), which in alternative approaches (eg, Western analysis) may not be possible at the microvascular level because of the need to homogenize the tissue. Separate measurements of the immunolabel density in the nucleus and in the cytoplasm also can be used to quantify nuclear translocation.
The nuclear translocation was prominent in the vessel walls of kidney and brain (Figures 2, 4) , showing a possibility that NFB activation in vessels in these tissues may be associated with endothelial dysfunction and further organ damage, such as renal failure and stroke. The endothelium of SHR microvessels exhibits enhanced apoptosis 8 together with enhanced oxygen free radical formation and enzymes that synthesize them, together with enhanced MMP expression. 18 The elevated NFB expression and activation found in glomerular and tubulointerstitial areas of the SHR are in agreement with previous studies in a renal model of hypertension. 40 The activation of NFB in myocardium ( Figure  3B ) also supports the association between myocardial infarction, hypertrophy, and hypertension. 41, 42 However, these results may have to be looked at from multiple perspectives, especially if apoptosis is present, as has been observed in several models of hypertension. 8, 10 The lack of a higher NFB expression level in myocardium ( Figure 1A, E) , as seen by immunohistochemistry, may be the consequence of extensive apoptosis. Cells that undergo apoptosis lose the ability to synthesize new proteins; therefore, the group of cells that are being analyzed in our experiments consists merely of those cells still capable of protein synthesis. Significant NFB expression in the SHR hypothalamus region but not in the cerebral cortex (Figure 1C, D , G, H) may suggest that hypertensive pathology is related to dysfunction of the hypothalamus because the output from the hypothalamus influences the nervous system and endocrine system, which in turn is associated with blood pressure control. 43 Blockade of NFB by PDTC treatment facilitates a number of improvements in different hypertensive models, including reduction of blood pressure, cardiac hypertrophy, and inflammatory cell infiltration into heart and kidney tissue. 9, 29, 37 In the current study, the systolic blood pressure was already lower in PDTC-treated SHR compared to nontreated SHR after 2 weeks of treatment ( Figure 5 ). The decreased blood pressure by PDTC inhibition in this study is also consistent with the fact that suppression of acute inflammation may lower the blood pressure in the Lyon hypertensive model. 44 The dose we used in this study (150 mg/day) has been applied in other studies without indication for toxic effect. 29 PDTC treatment also suppressed NFB expression level ( Figure 1 ) and serves to reduce the cleavage of ␤ 2 AR in the SHR (Figure 6 ). In our previous study, we identified a role of MMP cleaving ␤ 2 AR in SHR and its attenuation after MMP inhibition. 17 Therefore, we hypothesize that PDTC may have a similar effect on suppression of receptor cleavage attributable to inhibition of NFB-induced MMP expression. In the current study, the enhanced MMP-2 and MMP-9 activity in the SHR plasma was significantly decreased after the 10-week PDTC treatment (Supplemental Figure S3A, B) . This evidence is in line with the fact that blockade of NFB almost completely inhibits expression of MMP-9, and with the presence of NFB binding sites in the promoter region of MMP-9. 45 Furthermore, among different organs we found a mixed picture of NFB expression. For example, we did not see significantly decreased NFB expression in the myocardium after PDTC treatment. PDTC possibly may affect other transcription factors that can suppress blood pressure without changing the total NFB protein level.
WKY WKY+PDTC
Other off-target effects in addition to NFB expression of PDTC also may be involved in suppression of the receptor cleavage. Administration of PDTC in different rat models reduces angiotensin II-induced inflammation and inducible nitric oxide synthase expression. 37, 46 The antioxidant properties of PDTC have been shown to play an important role in several biological reactions. 32 Barki-Harrington et al 47 provided evidence for a direct physiological interaction between angiotensin and ␤-adrenergic receptors, both of which are G-protein-coupled receptors; therefore, it is possible that the inhibition of the angiotensin receptor signaling pathway may have an effect on ␤-adrenergic receptors as a potential feedback reaction. Because PDTC may have multiple activities, more studies using other inhibitors are required to distinguish its off-target effects from its ability to inhibit NFB.
Compared to WKY, SHR have elevated levels of MMP-2, MMP-1, and MMP-9 mRNA protein levels, 18, 48, 49 which is in line with the current results. Furthermore, our evidence suggests that MMP may cause cleavage of the extracellular domain of ␤ 2 AR in the kidney and the heart, which is consistent with previous studies showing reduced expression of this receptor as well as enhanced agonist-mediated desensitization in hypertension. 50, 51 Even though we did not observe significantly higher MMP-2 or MMP-1 and MMP-9 in the kidney, it is possible that other MMP activities could cause ␤ 2 AR cleavage and requires further examination.
One of the important issues associated with the proteolytic activity in the SHR is that it may cause not only cleavage of the extracellular domain of the ␤ 2 AR but also a variety of other surface receptors. Cleavage of the insulin receptor compromises the ability of insulin to signal intracellular glucose transport (insulin resistance 18 ), cleavage of the vascular endothelial receptor causes endothelial apoptosis and capillary rarefaction, 19 and cleavage of CD18 is associated with a reduced ability to mediate leukocyte adhesion to the endothelium in the SHR (immune suppression 18 ). Therefore, treatment targeting the proteolytic activity, be it by intervention against their expression levels or be it by suppression of their activity with pharmacological means, may serve as an approach to attenuate multiple forms of cell dysfunction and organ pathologies at the same time.
With exception of the vessels in the brain, we saw a significant reduction of ␤ 2 AR in the SHR that was consistent with our previous study. 17 The cleavage of this receptor contributes to endothelial dysfunction and vasoconstriction in arterioles and elevated central blood pressure. In addition, Rodrigues et al ( 17 ) demonstrated an attenuated response to ␤ 2 AR agonist and antagonist in SHR, also indicating the abnormal activity of this specific receptor compared to WKY control.
Perspectives
The current evidence suggests a role of NFB in triggering upregulation of MMP activity, which may cause cleavage of ␤ 2 AR as a mechanism that is involved in arteriolar/arterial constriction and pressure elevation. Chronic attenuation of NFB expression by PDTC serves to prevent ␤ 2 AR cleavage, restore the vasodilatory response in arteries/arterioles, and lower central blood pressure in the SHR. Based on the effect of PDTC on MMP expression and its antioxidant potential, 52 it may serve to reduce a variety of cell dysfunctions and attenuate end organ injury in hypertension.
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